Barry M. Sherman
Geen lopende functies
Profiel
Barry M.
Sherman was the founder of Cassava Sciences, Inc. (1998) and StemPar Sciences, Inc. (2012), where he held the titles of Chief Medical Officer & Senior Vice President and President & Chief Executive Officer, respectively.
He also founded BiPar Sciences, Inc. Dr. Sherman's former jobs include President & Chief Executive Officer of Anergen, Inc., Chairman of Angiogenix, Inc., Director of SillaJen Biotherapeutics, Inc., Director of National Institutes of Health, Chief Medical Officer & Senior Vice President of Genentech, Inc., Professor-Medicine & Endocrinology at the University of Iowa, and Advisor at Quantum Technology Partners.
He served as an Independent Director at Rezolute, Inc. from 2015 to 2017.
Dr. Sherman received his undergraduate and doctorate degrees from the University of Michigan.
Eerdere bekende functies van Barry M. Sherman
| Bedrijven | Functie | Einde |
|---|---|---|
| REZOLUTE, INC. | Directeur/Bestuurslid | 30-11-2017 |
Angiogenix, Inc.
 Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Voorzitter | 06-03-2008 |
| CASSAVA SCIENCES, INC. | Oprichter | 01-10-2001 |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Directeur/Bestuurslid | - |
| University of Iowa | Corporate Officer/Principal | - |
Opleiding van Barry M. Sherman
| University of Michigan | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CASSAVA SCIENCES, INC. | Health Technology |
| REZOLUTE, INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Anergen, Inc. | Health Technology |
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Health Technology |
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Quantum Technology Partners
 Quantum Technology Partners Investment ManagersFinance Quantum Technology Partners venture capital firm founded in 2000 by Barry Dickman. The firm is headquartered in San Jose, California. | Finance |
StemPar Sciences, Inc.
 StemPar Sciences, Inc. Medical/Nursing ServicesHealth Services StemPar Sciences, Inc. develops cancer drugs treatments. It provides cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and their ability to repair chemotherapy/radiation induced DNA damage. The company was founded by Hoyoung Huh and Mircea Florin Mihaescu in 2012 and is headquartered in Mill Valley, CA. | Health Services |
